Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MindBio Reports Sustained Antidepressant Response 3-Months Post Microdosing
Details : MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Brand Name : MB22001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 19, 2024
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MindBio Reports Sustained Antidepressant Response from MB22001 in Depression Trials
Details : MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Brand Name : MB22001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 20, 2024
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MindBio Reports Phase 2A Trial: Improved Outcomes in Depressed Patients
Details : MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Brand Name : MB22001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 12, 2024
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Psilocin Prodrug
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Recipient : Enveric Biosciences
Deal Size : $66.5 million
Deal Type : Licensing Agreement
Enveric Biosciences Signs $66.5 Million Term Sheet with MindBio for Psilocin Prodrug
Details : MindBio will seek to advance a drug candidate EB-002 (Psilocin Prodrug). Currently, it is being evaluated in the early-stage clinical trials studies for the treatment of depression, anxiety.
Brand Name : EB-002
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 14, 2024
Lead Product(s) : Psilocin Prodrug
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Recipient : Enveric Biosciences
Deal Size : $66.5 million
Deal Type : Licensing Agreement
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MindBio Receives Approval for Phase 2B Microdosing Mb22001 in Major Depressive Disorder
Details : MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Brand Name : MB22001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 04, 2024
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MindBio Therapeutics Reports Positive Depression Data from Phase 2a Microdosing Trial
Details : MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Brand Name : MB22001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 26, 2024
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
Details : MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Brand Name : MB22001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2024
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MindBio Nears Completion of Phase 2a LSD Microdosing Trial in Depressed Patients
Details : MB22001 (Lysergic acid diethylamide) is titratable form of LSD for take-home microdosing. It is being evaluated in phase 2 clinical trials for the treatment of Major Depressive Disorder.
Brand Name : MB22001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 30, 2024
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MB22001 (lysergic acid diethylamide) is a 5-HT2 receptor inhibitor, small molecule drug candidate. It is being evaluated for the treatment of depression in cancer patients.
Brand Name : MB22001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 28, 2023
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MB22001 is a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for safe and effective take home microdosing in patients suffering from Major Depressive Disorder.
Brand Name : MB22001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 24, 2023
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?